RPV-modified Epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Chemotherapy for non-small cell lung cancer (NSCLC) is far from satisfactory, mainly due to poor targeting of antitumor drugs and self-adaptations of the tumors. Angiogenesis, vasculogenic mimicry (VM) channels, migration, and invasion are the main ways for tumors to get nutrition. Herein, RPV-modified Epirubicin and dioscin co-delivery liposomes were successfully prepared. These liposomes exhibited ideal physicochemical properties, enhanced tumor targeting and accumulation in tumor sites, and inhibited VM channels formation, tumor angiogenesis, migration and invasion. The liposomes also down-regulated VM-related and angiogenesis-related proteins in vitro. Furthermore, when tested in vivo, the targeted co-delivery liposomes increased the selective accumulation of drugs in tumor sites and exhibited extended stability in blood circulation. In conclusion, the RPV-modified Epirubicin and dioscin co-delivery liposomes exhibited strong antitumor efficacy in vivo and could thus be considered a promising strategy for NSCLC treatment.